Astellas seeks new Xtandi indication

Share this article:

Astellas and Medivation have made pursuit of a pre-chemo indication for Xtandi official: the two companies announced Tuesday that they have filed a supplemental New Drug Application with the FDA so the oral drug can be used by metastatic castration-resistant prostate cancer patients earlier in treatment.

The drug is currently approved for patients who have already received docetaxel. The companies released the Phase-III data that is the basis of Tuesday's submission in January. The data indicated that an earlier intervention bought patients progression-free time.

Phase-III results also indicated that prostate-specific antigen levels fell by at least 50% among 75% of the test group, and overall survival was 29% greater with pre-chemo use compared to placebo.

Adding a pre-chemo indication to a post-chemo drug is not a new strategy: Roche moved its breast cancer drug Perjeta into first-line treatment for early stage breast cancer patients in September.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.